Achillion has a successful track record of collaborating with third parties to maximize the value of our clinical candidates by leveraging the financial, clinical, regulatory, manufacturing and commercialization strengths of our partners.
Achillion previously licensed its self-discovered NS5A HCV antiviral, ACH-3102, to Janssen Pharmaceuticals Inc., of Johnson & Johnson, as well as partnered additional antiviral assets in other therapeutic areas.
We seek to maximize the impact of our oral factor D complement inhibitor portfolio by partnering with leading academic institutions, government agencies, and pharmaceutical companies. We are particularly focused on ex-US partnerships clinical and commercial partnerships with leading biopharmaceutical companies and are keenly interested in accessing investigator, academic and corporate-sponsored agreements to extend the breadth of indications that our complement platform can address.
If you’re interested in learning more about our portfolio opportunities, please contact us below.